An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Article

Abstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the

Palabras claves:

covid-19, Cytokine release syndrome, IL-6, Itolizumab

Autores:

Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.

Fuentes:

scopus